Discover insights from leading Australian and International experts in heart failure.                                                                                                                                                                                                                                                                                                                                                                                          

 


AU-13388

Essential tips for optimising treatment in your patients with HFrEF Professor Andrew Sindone

To watch the full presentation click here  

 

AU-13260

The Hidden Symptoms of Heart Failure: How to find them and how to act Professor Andrew Sindone

To watch the full presentation click here  

 

AU-13034

 

Heart Failure. A GP disease state: A guide to optimising your patient’s treatment Professor Andrew Sindone

To watch the full presentation click here  

AU-6183

When should a GP intervene in a patient's heart failure management? Dr Gary Deed and Dr Anita Sharma

 

AU-6175

Why should there be an urgency to treat a heart failure patient? A/Prof. John Atherton

 

 

AU-6185

Who is the right patient for a GP to initiate Entresto on? Dr Gary Deed and Dr Anita Sharma

 

 

 

Mechanisms of myocardial injury from COVID-19 and the clinical implications Dr Yee Weng Wong

 

 

 

Should we avoid ACEI ARB medications in COVID-19 patients? Dr Yee Weng Wong

 

 

 

Chronic Heart Failure and COVID-19: What you need to know in 90 seconds Dr Yee Weng Wong

 

 

 

Why HF Hospitalisation Matters  Dr Scott McKenzie

 

 

Re-framing HF Hospitilisation  Dr Scott McKenzie

 

 

COVID-19 and HF Questions Answered  Dr Scott McKenzie

 

What is your experience with treating an in-hospital patient with Entresto? Professor Fabian Knebel

 

 

When should a clinician consider switching a stable patient to Entresto? Professor Fabian Knebel

 

 

Are there any stable heart failure patients? Professor Fabian Knebel

 

 

Reference:
1. ENTRESTO Approved Product Information, 08 November 2017.

 

Entresto is indicated in adult patients for the treatment of chronic heart failure (NYHA Class II-IV) with reduced ejection fraction.

 

PBS Information : Authority required (STREAMLINED) for chronic heartfailure. Patients must be NYHA Class II–IV, have LVEF ≤40% and be receiving optimal standard chronic heart failure treatment.

Refer to PBS Schedule for full Authority Information.

 

SEE APPROVED PRODUCT INFORMATION BEFORE PRESCRIBING. FOR THE MOST UP TO DATE PRODUCT INFORMATION CLICK HERE.

AU-5788
×

Medical Information Request